Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · lung-landscapes@6

X1ce4a106.c532.4678.a6de.8e89f5123c73

— · cohortMD2

b52ae8ce-2990-565e-b05d-c9bd308f56b5

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
cohortMD2
subtype
cohortMD2
age_years
71

GSVA pathway preview (0 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

HTTPException: HTTP Error: Request returned HTTP 429 for HTTP HEAD to 'https://pub-e056b053afc04eec88337b62541f3025.r2.dev/oncoscape/lung-landscapes/6/gsva.parquet' LINE 1: SELECT pathway_library_id, pathway_name, gsva_score FROM read_parquet('https://pub-e056b053afc04eec88337b62541f3025... ^

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-73-4666-01A-01R-1206-07
lung-landscapes@6
—cohortA10.859
2ERR2208906
melanoma-umap@29
——0.858
3TCGA-39-5011-01A-01R-1443-07
lung-landscapes@6
—cohortA10.855
4C3N-03764
lung-landscapes@6
—cohortA10.854
520070130.TNBC
breast-umap@18
—C0.849
6KCL22_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
ccle-cml@v2024.1
CML—0.849
7SRR12696807
melanoma-umap@29
——0.848
8TCGA-AO-A0J2-01A-11R-A034-07
breast-umap@18
—C0.847
9MNG533
mng-umap@100
——0.846
10P31FUJ_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
ccle-aml@v2024.1
AML—0.844

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 37 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_ALPHA_RESPONSE0.640Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.520Idelalisib— uncovered
E2F_TARGETS0.500Inavolisib— uncovered
ALLOGRAFT_REJECTION0.430Idelalisib— uncovered
G2M_CHECKPOINT0.360Inavolisib— uncovered
ANDROGEN_RESPONSE0.350Inavolisib— uncovered
PEROXISOME0.340Idelalisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.330Remibrutinib— uncovered
MYC_TARGETS_V10.330Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.320Remibrutinib— uncovered
DNA_REPAIR0.290Idelalisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.290Inavolisib— uncovered
MTORC1_SIGNALING0.270Inavolisib— uncovered
FATTY_ACID_METABOLISM0.260Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.260Inavolisib— uncovered
HEME_METABOLISM0.250Temsirolimus— uncovered
UNFOLDED_PROTEIN_RESPONSE0.250Idelalisib— uncovered
APOPTOSIS0.240Idelalisib— uncovered
BILE_ACID_METABOLISM0.230Inavolisib— uncovered
COMPLEMENT0.220Inavolisib— uncovered